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ABSTRACT
Background: Upper gastrointestinal tract (GIT) bleeding on liver cirrhosis patients will increase
morbidity and mortality. Recurrent bleeding’s risk rise after the first episode of variceal bleeding. The
mortality risk also rises on each bleeding.
Purpose: This study was done in order to identify the risk factors for the first episode of recurrent
bleeding of upper GIT on liver cirrhosis patient. Evaluation of risk factors was based on preliminary data
prior to ligation.
Method: Evaluation of the upper GIT bleeding was done using anamnesis on the patients or their
relatives by letter, home visits or telephone. The data on recurrent bleeding was obtained from medical
records. They were evaluated on the 3rd month then 1st year after ligation. This study was a cross sectional
study with retrospective data and a consecutive sampling method.
Result: Bivariate analysis revealed the 3rd month’s risk factors for first episode of upper GIT bleeding
were ascites, total bilirubin level of > 2 mg/dL, hepatoma, Child-Pugh C classification of the liver function
and red color sign on esophageal varices. The risk factors for the first episode of upper GIT bleeding on
first year were age ≤ 60 years old, hepatoma, and red color sign (RCS) on esophageal varices.
The differences between risk factors on upper GIT bleeding on the 3rd month and 1st year were likely due to
intervention, collateral para-esophageal varices, medication that irritated GIT, physical activities, and
differences on variceal obliteration rate related to variceal ligation.
Conclusion: Risk factors for recurrent upper GIT bleeding that could be minimized were ascites, total
bilirubin level, Child-Pugh classification and RCS. It was expected with parascentesis, diuretics,
hepatoprotector medications and drugs that lowers portal hypertension (such as propranolol and isosorbid
mononitrate), might improve those risk factors thus decreasing the risk for recurrent upper GIT bleeding.
Keywords: Upper gastrointestinal tract, esophageal varices, liver cirrhotic.
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INTRODUCTION
Liver cirrhosis mortality on 38 countries in America,
Europe, Africa and Asia from 1985 until 1990 was 3 to
40 /100,000 people. The worldwide prevalence of liver
cirrhosis in 1993 was between 25 and 40 cases/100,000
people. About 90% cases of liver cirrhosis resulted in
portal hypertension and 1/3 die due to upper
gastrointestinal track (GIT) bleeding.1 A survey
conducted by The Indonesian Ministry of Health in 1996
revealed 4.2% of mortality caused by chronic liver
disease and liver cirrhosis.2 Liver cirrhosis and portal
hypertension might increase the probability for liver
cirrhotic to 35% to 85%. Liver cirrhosis with esophageal
varices might increase the risk for bleeding up to 25% to
30%,3 the risk for recurrent esophageal bleeding in one
year increases around 30% to 40%,4 and death due to
recurrent bleeding increase more than 50%.5
A study conducted by Djojoningrat in Department of
Internal Medicine, Cipto Mangunkusumo hospital,
showed mortality from upper GIT bleeding was around
26%. From those, 23% was attributable to hypovolemic
shock. Endoscopic examination showed most lesions
were esophageal varices (70%).6 A study by Abdoellah
M et al., on Ramelan Navy hospital in Surabaya in 1999
revealed 78% incidence of esophageal varices in
patients with hematemeses and melena.7 In Sardjito
Hospital in Jogjakarta, there were 42.1% liver cirrhosis
patients died caused by with hepatic coma preceded by
GIT bleeding.8
Prognosis for a non-variceal bleeding is better than
variceal bleeding. The severity of variceal rupture
bleeding are attributed to more complications, more blood
needed for transfusion, complex management, and higher
mortality.9 Therefore, hematemeses and melena are
warning signs, which causes must be searched for, and
preventions for recurrent bleeding must be taken.10
Factors involve in the first episode of variceal
bleeding are Child-Pugh classification, the size of
esophageal varices, and red wale marking on esophageal
varices wall.11,12 Other predictors are cherry-red spot,
elevated serum bilirubin level, portal vein congestive
index (portal vein’s diameter and portal blood velocity).13
Also encephalopathy, ascites and age have correlation
to mortality.11
Factors associated to early upper GIT bleeding
(< 6 weeks) are severity of first bleeding period,
age > 60 years old, severity of hepatic function, ascites,
encephalopathy, and disturbance on kidney function,
active bleeding on first time endoscopic examination,
stigmata on varices, platelet clot in varices, and the size
of varices.14,15 Factors involved in late recurrent
bleeding (> 6 weeks) are severity of liver function,
ascites, hepatoma, active alcohol drinker and red sign on
endoscopy.15 Other study revealed factors for recurrent
bleeding such as albumin < 3 g/dL and active variceal
bleeding on endoscopy index.16 Another study found age,
cirrhotic etiology, ascites, variceal size and Child-Pugh
classification had no correlation on recurrent variceal
bleeding.16,17
Other methods for predicting variceal bleeding is
variceal pressure. North Italian Endoscopic Club (NIEC)
index plus variceal pressure measurement will increase
prediction of variceal bleeding incidence.18 These
conclude that clinical findings and endoscopic data are
valuable information for estimating the risk of bleeding.19
Standard treatments on esophageal varices might
prevent recurrent bleeding. Those treatments would be
ligation, sclerotherapy and/or medications.20 Study in
Cipto Mangunkusumo hospital in 1989 showed variceal
sclerotherapy could lower the incidence of recurrent
bleeding.21 Recently ligation is more popular than
sclerotherapy because sclerotherapy have higher
incidence for recurrent bleeding than ligation.16,17,22 Also
one meta-analysis study showed the complication of
ligation was lesser than sclerotherapy.23 Three
studies conducted by Hata et al., Lo et al., and Hou et
al., showed there were no difference in the incidence of
recurrent bleeding in ligation and sclerotherapy.24-26
Bleeding from gastric varices was more common in
sclerotherapy than in ligation. Bleeding incidence also
tends to be higher in unobliterated varices.26 Ligation
can control 94% of acute variceal bleeding22 and also
prevents recurrent variceal esophageal bleeding up to
25%.14
This study was done to obtain the prevalence of
the first episode of recurrent upper GIT bleeding after
the first ligation of esophageal varices in the 3 month
and 1 year period after the treatment and to have
knowledge of the risk factors for the recurrence of   upper
GIT bleeding after first ligation of esophageal varices in
liver cirrhotic patient. Risk factors were observed from
clinical signs and upper GIT endoscopic before ligation.
METHOD
This was a cross sectional study with recurrent
upper GIT bleeding as outcome variable, which would
be evaluated in 3 months and 1 year after the first
ligation of esophageal varices.
Volume  5, Number 3, December 2004 81
Risk Factors for Recurrent Upper Gastrointestinal Tract Bleeding after Esophageal Varices Ligation on Patients with Liver Cirrhosis
Population and sample
Target populations were patients with esophageal va-
rices due to liver cirrhosis with history of upper GIT bleed-
ing, who had not had any variceal ligation. Population
within reach: liver cirrhosis patients who had been per-
formed esophageal varices ligation. Sample was patients
who had been performed esophageal varices.
Data collection
Inclusion criteria were liver cirrhosis patients who
had esophageal varices with upper GIT bleeding before
ligation of the varices.
Exclusion criteria were patient whose medical record
was damaged or lost, no clinical/laboratory data
before esophageal varices ligation, patient died due to
non-bleeding cause during evaluation period,
incomplete address hindered communication through
letters, telephone or home visits.
Baseline data before ligation were retrospective,
including age, gender, physical examination (level of
consciousness and ascites), laboratory data (serum
albumin level, total bilirubin level, prothrombin factor, and
thrombocyte count), Child-Pugh classification,
abdominal  ultrasonography (cirrhosis appearance,
ascites, portal hypertension, hepatoma) and
esophagogastroduodenoscopy (RCS appearance,
esophageal varices size, cardia/fundal varices and PHG).
Data collected after the first ligation were recurrent
upper GIT bleeding (description of hematemeses or
melena). These data based on anamnesis on patients or
family members by telephone, letters, home visits, and
medical records. Data on upper GIT bleeding then
evaluated in 3 months time and in 1 year time.
RESULTS
There were 72 cases satisfying the inclusion criteria
in the 3rd month evaluation period. In one year
evaluation period there were only 71 cases because one
patient died due to non hemorrhagic cause. The
remaining cases then analyzed for recurrent upper GIT
bleeding based on clinical and laboratory data prior to
ligation. Forty three data on recurrent upper GIT
bleeding were obtained from anamnesis on the patients
or family members and 29 cases obtained from medical
records. Data on risk factors and upper GIT recurrent
bleeding then were analyzed using univariate and
bivariate models. Analysis of those data then divided into
2 parts.
Analysis on the data from the 3rd months after
ligation
a. Clinical and endoscopic feature of esophageal
variceal ligation
From 72 ligated esophageal varices cases, 14 cases
(19.4%) experienced recurrent upper GIT bleeding
within 3 months. There were 45 cases (62.5%) of
male patients and 27 cases (37.5%) of female
patients with mean age 55.5 years old. Child-Pugh
classification A and B were 67 cases and Child-Pugh
C was 5 cases. Hepatoma patients were 10 people.
Endoscopic findings prior to ligation were 4 people
with grade one and two esophageal varices, and 68
people with grade 3 and 4. There were 21 people
with esophageal varices and RCS, and 4 people with
esophageal varices along with cardia/fundal varices.
There were 49 people with esophageal varices with
portal hypertensive gastropathy (PHG.)
b. Risk factors for recurrent upper GIT bleeding from
clinical and endoscopy features during 3rd month
evaluation period.
Bivariate analysis on 3rd month group found some
variables that act as risk factors for recurrent GIT
bleeding had p ≤ 0.05. They were:
• Total bilirubin > 2 mg/dL, increased the risk for
having recurrent upper GIT bleeding by 4.7 times
compared to total bilirubin of ≤ 2 mg/dL [OR =  4.688
and CI = 1.284-17.117]
• The presence of ascites, increased the risk for
having recurrent upper GIT bleeding by 4.5 times
compared to no ascites  [OR = 4.513 and CI = 1.138-
17.893]
• The presence of hepatoma, increased the risk for
having recurrent upper GIT bleeding by 18 times
compared to no hepatoma [OR = 18.33 and CI =
3.835-87.645]
• Child-Pugh C classification, increased the risk for
having recurrent upper GIT bleeding by 7.6 times
compared to Child-Pugh A and Child Pugh B
classification [OR = 7.636 and CI = 1.139-51.117]
• The presence of RCS, increased the risk for having
recurrent upper GIT bleeding by 4.6 times compared
to no RCS  [RR = 4.615 and CI = 1.355-15.716]
The analysis also showed variables that were not
act as risk factors for recurrent GIT bleeding (P > 0.05),
they were age ≤ 60 years old, thrombocyte
< 100,000 µL, albumin < 3.5 g/dL, PT > 17 seconds,
esophageal varices grade 3 & 4, presence of fundal/
cardial varices and PHG degree moderate & severe.
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T able 1 . C linica l an d E nd oscopic C haracteristic o f L igated  E so phagea l V arices  Pa tients 
D uring  3 r d M onth  E valuation  Perio d 
Variable N Mea n M edian  SD  M inim um  Maxim um  
Ag e  55 .5 58  1 0.3 28 71  
 = 60 
>  60  
4 7 
2 5 
     
Thrombocyte (per  µ L)  1 20,947 96,500 79 ,414  31 ,000  520,000 
 < 10 0,000 
= 10 0,0 00 
3 7 
3 5 
     
To tal b iliru bin  (m g/dL)   2.0 1.3 3 .0  0 .2  24 .5  
 = 2  
> 2  
1 4 
5 8 
     
Alb umin   3.1 3 0 .7  1 .8  5 
 < 3 .5  
= 3 .5  
5 6 
1 6 
     
Proth ro mbin  (s econd)  14 13 .6  2 .3  10 20  
 > 17  
= 17 
8  
6 4 
     
As cites       
 Positive 
Negative 
3 7 
3 5 
     
Child-Pu gh  score       
 Ch ild C 
Child A and B 
5  
6 7 
     
Hepatoma       
 Positive 
Negative 
1 0 
6 2 
     
Red co lor  sign        
 Positive 
Negative 
2 1 
5 1 
     
Eso phageal varices  size       
 Grade 3  and 4 
Grade 1  and 2 
6 8 
4  
     
Card ia/fundal var ices       
 Positive 
Negative 
4  
6 8 
     
PH G       
 M oderate/sev ere 
M ild 
4 9 
2 3 
     
N  =  Number of  patient; SD  = stand ard  dev iation  
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Analysis on the data from 1st year after ligation
a.  Clinical and endoscopic feature of patients with
ligated esophageal varices (see table 3.)
On the first year evaluation, there were 71 ligation
cases which met inclusion and exclusion criteria, 28
people (39.4%) experienced first episode of
recurrent bleeding during 1 year after ligation.
Clinical characteristics of this group were 45 people
(63.4%) male and 26 people (36.6%) were female.
Mean age was 55.4 years old, Child-Pugh A & B
classification were 66 people, Child-Pugh C
classification were 5 people. Endoscopic
characteristics before esophageal varices ligation
were grade 3 and 4 esophageal varices were 68
people and grade 1 and 2 were 3 people.
b. Risk factors for recurrent upper GIT bleeding from
clinical and endoscopy features during 1st year
evaluation period.
There were some variables acting as risk factors
for recurrent GIT bleeding with P ≤ 0.05 are follow as:
• Age ≤ 60 years old increased the risk for bleeding
by 2.9 times compared to > 60 years old [OR = 2.903
and CI = 0.981-8.590]
• Hepatoma increased the risk for bleeding by 4.4 times
compare to non hepatoma [OR = 4.444 and CI =
1.040-18.985]
• RCS increased the risk for bleeding by 3.8 times
compared to no RCS [RR = 3.792 and CI = 1.303-
11.037]
Table  2. Risk Factors for Recurrent Upper GIT Bleeding during 3rd  Month Per iod 
Variable Recurrent Bleeding Prevalence P OR 95% CI P ositive Negative (%) Lower Upper 
A ge    0.758    
 = 60 
>  60  
10 
4 
37 
21 
2 1.3 
1 6.0 
 1.419 
1 
0.396 5.089 
T hrombocyte (per µL)    0.191    
 < 100,000 
= 100,000 
5 
9 
32 
26 
1 3.5 
2 5.7 
 0.451 
1 
0.135 1.513 
T otal bilirubin (mg/dL)    0.014    
 = 2 
> 2 
6 
8 
8 
50 
4 2.9 
1 3.9 
 4.668 
1 
1.284 17.117 
A lbumin    0.497    
 < 3.5  
= 3.5  
10 
4 
46 
12 
1 7.9 
2 5.0 
 0.652 
1 
0.174 2.447 
P rothrombin (second)    0.648    
 > 17 
= 17 
2 
12 
6 
52 
25 
1 8.8 
 1.444 
1 
0.259 8.058 
A scites    0.036    
 Positive 
Negative 
11 
3 
26 
32 
2 9.8 
8 .6 
 4.513 
1 
1.138 17.893 
Child-Pugh score    0.047    
 Child C 
Child A and B 
3 
11 
2 
56 
6 0.0 
1 6.4 
 7.636 
1 
1.139 51.11 
H epatoma    0.000    
 Positive 
Negative 
7 
7 
3 
55 
7 0.0 
1 1.3 
 18 .33 
1 
3.835 87.645 
Red color sign    0.010    
 Positive 
Negative 
8 
6 
13 
45 
3 8.1 
1 1.8 
 4.615 
1 
1.355 15.716 
Es ophageal varices size    1.000    
 Grade 3  and 4 
Grade 1  and 2 
13 
1 
55 
3 
1 8.8 
2 5.0 
 0.709 
1 
0.068 7.380 
Cardia/fundal varices    1.000    
 Positive 
Negative 
1 
13 
3 
55 
2 5.0 
1 8.8 
 1.410 
1 
0.136 14.677 
P HG     0.525    
 Moderate/severe 
Mild 
11 
3 
38 
20 
2 2.5 
1 3.0 
 1.930 
1 
0.482 7.722 
N ote: CI =  confidence interval, OR =  odds ratio, N  = number of patient 
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Table 3. Clinical and Endoscopic Characteristic of Ligated Esophageal Varices Patients 
During 1st Year Evaluation Period 
Variable N = 71 Mean Median SD Minimum Maximum 
Age  55.4 58 10.33 28 71 
 = 60 
>  60 
46 
25 
     
Thrombocyte (per µL)  122,157 98,000 79,307 31,000 520,000 
 < 100,000 
= 100,000 
36 
35 
     
Total bilirubin (mg/dL)  2.0 1.3 3.1 0.2 24.5 
 = 2 
> 2 
14 
57 
     
Albumin  3.1 3.0 0.7 1.8 5 
 < 3.5 
= 3.5 
55 
16 
     
Prothrombin (second)  14 13.7 2.2 10.0 20 
 > 17 
= 17 
8 
63 
     
Ascites       
 Positive 
Negative 
37 
34 
     
Child-Pugh score       
 Child C 
Child A and B 
5 
66 
     
Hepatoma       
 Positive 
Negative 
10 
61 
     
Red color sign       
 Positive 
Negative 
21 
50 
     
Esophageal varices size       
 Grade 3 and 4 
Grade 1 and 2 
68 
3 
     
Cardia/fundal varices       
 Positive 
Negative 
4 
67 
     
PHG       
 Moderate/severe 
Mild 
48 
23 
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Variables that were not acting as risk factors for
upper GIT bleeding (P > 0.05) were thrombocyte
< 100,000/µL, total bilirubin 2 mg/dL, PT > 17 second,
presence of ascites, Child-Pugh C, esophageal varices
grade 3 & 4, cardia/fundal varices and mild & moderate
PHG
DISCUSSION
This was a cross sectional study using retrospective
data therefore had few limitations such as the presence
of interventional therapy, which might interfere with
clinical and biochemical manifestations, thus altered the
incidence of recurrent GIT bleeding. In order to reduce
this bias, the patients were assumed having proportional
and equally distributed interventional therapy and upper
GIT bleeding data were obtained from anamnesis.
Uncontrollable factors yet having significant effects on
this study were unidentifiable source of recurrent upper
GIT bleeding, after ligation medications and length of
therapy and the presence of esophageal varices
obliteration after ligation.
There were 72 cases fulfilling inclusion criteria at 3rd
month evaluation and 71 cases at 1st year evaluation.
From those cases, the incidence of recurrent bleeding
during 3 months was 19% and during 1 year was 39%.
Mean age of the samples was 55 years old, not
significantly different from those reported by one
meta-analysis which sample’s age spread between 46
to 56 years old. This was true for upper GIT recurrent
bleeding estimation of 30%.23
Risk factors for the first episode of recurrent
bleeding were evaluated on the 3rd month and 1st year
time. These evaluation periods were decided in order to
evaluate the influence of local factors, or any difference
in risk factors for the first episode of recurrent bleeding
between evaluation periods. There were other studies
T ab le  4 . Ri sk  Fac tors  for R ec urr en t Up p er G IT B lee ding d u rin g 3 rd  M on th  Per iod  
V ariable R ecu rre nt B lee ding (N  =  71) Pre valen ce  P OR  95%  CI  Pos iti ve Ne gative (% ) L ow er Up p er  
A ge     0.05     
 = 6 0 
>  60  
2 2  
6 
24  
19  
47.8  
24.0  
 2.903 
1  
0 .981 8 .590 
T hrom b ocy te  (p er µ L )     0.561    
 < 1 0 0,00 0 
= 1 0 0,0 0 0 
1 3  
1 5  
23 
20  
36.1  
42.9  
 0.754 
1  
0 .290 1 .957 
T ota l bil ir ub in ( m g /d L )    0.367    
 = 2  
> 2  
7 
2 1  
7  
36  
50  
36.8  
 1.714 
1  
0 .528 
 
5 .567 
A lbu m in    0.857    
 < 3 .5  
= 3 .5  
2 2  
6 
33  
10  
40  
37.5  
 1.111 
1  
0 .353 3 .498 
P ro thro m b in (secon d )    0.730    
 > 1 7  
= 1 7 
3 
2 5  
5  
38  
37.5  
39.7  
 0.912 
1  
0 .200 4 .160 
A scite s    0.098    
 Po sit ive  
Neg ative  
1 8  
1 0  
19 
24  
48.7  
29.4  
 2.274 
1  
0 .854 6 .056 
C h ild -Pu g h s cor e    0.376    
 Ch ild C 
Ch ild A an d B 
3 
2 5  
2  
41  
60  
37.9  
 2.460 
1  
0 .384 15 .756 
H epato m a     0.043    
 Po sit ive  
Neg ative  
7 
2 1  
3  
40  
70  
34.4  
 4.444 
 
1.04 18 .985 
R ed  co lo r sig n    0.012    
 Po sit ive  
Neg ative  
1 3  
1 5  
8  
35  
61.9  
30  
 3.792 
1  
1 .303 11 .037 
E s op hag ea l varices size     1.000    
 Grade  3  an d 4 
Grade  1  an d 2 
2 7  
1 
41  
2  
39.7  
33.3  
 1.317 
1  
0 .114 15 .249 
C ardia /fun d al v arices    0.293    
 Po sit ive  
Neg ative  
3 
2 5  
1  
42  
75  
37.3  
 5.040 
1  
0 .497 51 .116 
P HG     0.971    
 Mo d er a te /sev ere  
Mild 
1 9  
9 
29  
14  
39.6  
39.1  
 1.019 
1  
0 .368 2 .820 
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evaluating the recurrent bleeding using period < 6 weeks
and > 6 weeks; or on the 1st and 2nd year. Risk factors
that were evaluated include clinical and biochemical
features before ligation, such as age, serum albumin level,
total bilirubin level, thrombocyte count, prothrombin time,
the presence of ascites, Child-Pugh classification, the
presence of hepatoma, RCS, measurement of
esophageal varices, the presence of cardia/fundal
varices, and PHG.
On the 3rd month evaluation, age was not a factor for
recurrent upper GIT bleeding; on the contrary, on the 1st
year evaluation age ≤ 60 years old was one of the
factors of recurrent upper GIT bleeding. This finding did
not correlate with result from other study that showed
age > 60 years old as one of the factors for recurrent
upper GIT bleeding.16 A study by Gimson et al., revealed
age had no correlation with variceal bleeding.17 These
differences were probably due to variation in post
ligation therapy, physical activities, paraesophageal
collateral formation that might interfere with portal
pressure. All of these circumstances might influence the
occurrence of upper GIT bleeding, which warrants
further study.
On both 3rd month and 1st year evaluation period
thrombocyte count 100,000/µL was not a risk factor for
upper GIT bleeding; this was also shown by other
study.14,15,22 On 3rd month and 1st year evaluation
periods, albumin was not a risk for upper GIT bleeding.
This did not correspond to other study’s finding which
showed albumin < 3 g/dL as one factor for recurrent
upper GIT bleeding.22 This difference might be
contributed by the difference in cut of point, and
the categorization of albumin in this study into < 3.5 g/dL
and ≥ 3.5 g/dL and the elevation of albumin level due to
intervention.
In this study prothrombin time > 17 seconds was not
a risk factor for recurrent upper GIT bleeding, as other
study had shown.14,15,22 Total bilirubin level is a
component of Child-Pugh classification for assessing the
severity of liver cirrhosis. Siringo et al., showed bilirubin
was an independent predictor for first episode of
variceal bleeding.13 This study showed total bilirubin of
> 2 mg/dL as risk factor for recurrent upper GIT
bleeding in the 3rd month evaluation period, but not for
1st year evaluation period. This was probably due to
intervention and bilirubin level decreasing over time. On
3rd month evaluation time, ascites was found as one of
risk factors for recurrent upper GIT bleeding, but not on
the 1st year evaluation period. The finding was
concordant to other studies.15 On the contrary, Gimson
et al., did not find correlation between ascites and
recurrent variceal bleeding.16 The difference between
3rd month and 1st year findings most likely due to the
estimation of ascites used in this study based only on
physical examination and ultrasonography and coded as
positive and negative without estimating the severity
gradation of ascites. Another possibility was
intervention given before upper GIT bleeding. If
ligation was going to be done on liver cirrhosis patient
with ascites, it was preferred treating the ascites
before the procedure, because severe ascites might
interfere with ligation procedure. The dispersal of
ascites might decrease recurrent bleeding. In emergency,
variceal ligation can be done regardless ascites status.
In liver cirrhosis, decreased liver function might
correlate with the amount of anatomical anomalies of
the liver, which influence progression of portal pressure.
However, variceal enlargement does not correlate with
progression of portal hypertension.27 On lower grade
cirrhosis, this has correlation with anatomical anomalies
of the liver, which in turn, increases the risk for bleeding.
AASLD suggest endoscopic screening procedure on liver
cirrhosis Child-Pugh classification B & C.28 On third
month evaluation period, Child-Pugh C was one of risk
factors for recurrent upper GIT bleeding, but not in 1st
year evaluation period.
The difference in duration and intervention might
create variations in risk factors for bleeding between 3rd
month and 1st year evaluation period; this might have
relationship to the reduction of Child-Pugh classification.
According to researches by Lo GH and Olmo et al.,
Child-Pugh classification might have association to
recurrent upper GIT bleeding.22,29 On the contrary,
De la Pena et al., found no association between
Child-Pugh classification and recurrent variceal
bleeding.17
Hepatoma was one of the risk factors for recurrent
upper GIT bleeding on 3rd month and 1st year evaluation
period. Portal pressure increased in hepatoma with
thrombus inside the portal vein. Liver ultrasonography in
our study could not find any portal vein thrombus
because was not done by the same person. Another study
found hepatoma as risk factors for recurrent variceal
bleeding in > 6 weeks but not for < 6 weeks.15 This
difference might be attributed to the stadium, location,
size, presence of thrombus inside the portal vein and the
shape, and therapy given. Our study did not evaluate
these terms, thus in order to evaluate the influence of
hepatoma on the recurrence of the upper GIT bleeding
warrants further study. To estimate the benefit of
ligation on hepatoma patients also needs further study.
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The presence of RCS has correlation to the incidence
of variceal bleeding.11,12 In this study, bivariate analysis
on 3rd month and 1st year evaluation period indicate RCS
as one of risk factors for recurrent upper GIT bleeding.
RCS marks a thinning on variceal wall due to increasing
pressure inside. Increasing intra variceal pressure will
strain the variceal wall, making it thinner, and easier to
bleed. Other study also concur that RCS on esophageal
varices was a risk factor for recurrent variceal
bleeding.15
Several studies demonstrated the size of the varices
was a risk factor for recurrent upper GIT bleeding.14,15,22
However, this study did not reflect those findings. This
difference occurred probably due to insufficient cases
of low-grade esophageal varices studied (4 of 72). Thus,
there should be a case-control study to measure the
importance of variceal size on variceal bleeding.
Gastric varices contributed 5% to 10% from all
variceal bleeding.30 This kind of varices was usually more
severe compared to esophageal varices.31 The presence
of cardia/fundal varices was an initial prognostic factor
for of variceal bleeding.32 However, in this study cardia/
fundal varices did not become one of risk factors for
recurrent upper GIT bleeding. This was probably due to
insufficient cases of cardia/fundal varices (4 of 72). This
also warrants further case-control study. Other study
found the prevalence of PHG was between 4% to 98%.33
Bleeding from PHG was even rare, between 2 to 3%.30,34
Gastropathy congestive index was a prognostic factor
for the first episode of upper GIT bleeding.32 In this study,
PHG was not a risk factor for recurrent upper GIT
bleeding which also shown by other studies.14,15,22
The overall conclusions from this study were risk
factors for recurrent upper GIT bleeding in 3rd month
evaluation period were ascites, total serum bilirubin
> 2 mg/dL, hepatoma, Child-Pugh C classification and
RCS. Risk factors that did not have any correlation in
3rd month recurrent upper GIT bleeding were age,
 thrombocyte count, albumin level, PT, esophageal
varices size, fundal/cardia varices and PHG. Risk
factors for 1st year evaluation period of recurrent upper
GIT bleeding were age ≤ 60 years old, hepatoma and
RCS. Risk factors that did not have any correlation were
thrombocyte count, albumin level, PT, total bilirubin, the
presence of ascites, Child-Pugh classification, esophageal
varices size, cardia/fundal varices and PHG.
The difference in risk factors for recurrent bleeding
between the 3rd month and 1st year evaluation period
were probably due to intervention and alteration of risk
factors over time. Other factors that might interfere
before recurrent upper GIT bleeding were
para-esophageal collateral, drugs that irritate GIT,
alteration in physical activity, and obliteration rate of the
varices related to ligation therapy. This study did not
evaluate those factors, thus warrants further study.
By knowing the risk factors for recurrent upper GIT
bleeding on esophageal varices ligation, we could obtain
additional information to predict the risk for recurrent
bleeding after a ligation procedure. Therefore, by
improving or eliminating those risk factors before
ligation procedure will reduce the risk for recurrent
bleeding after the procedure. Ascites, total serum
bilirubin, Child-Pugh classification and RCS are the risk
factors that can be improved by diuretics,
hepato-protector, and portal pressure lowering drugs
(such as propanolol and isosorbid mononitrate).
CONCLUSION
Risk factors for recurrent bleeding after preliminary
ligation of esophageal varices are age ≤ 60 years old,
ascites, total serum bilirubin > 2 g/dL, hepatoma,
Child-Pugh C and RCS. Further, those factors can be
divided into 2 groups, which are:
• Within 3rd month evaluation period are total bilirubin
> 2 mg/dL have 4.7 times the risk compare to
< 2 mg/dL, the presence of ascites have 4.5 times
the risk compare to no ascites, the presence of
hepatoma have 18 times the risk compare to no
hepatoma, Child-Pugh C have 7.6 times the risk
compare to Child-Pugh A and B and RCS on
varices have 4.6 times the risk compare to no RCS.
• Within 1st year evaluation period are age ≤ 60 years
old have 2.9 times the risk compare to age > 60 years
of age, the presence of hepatoma have 4.4 times the
risk compare to no hepatoma and red color sign have
3.8 times the risk compare to no RCS.
SUGGESTION
Risk for recurrent bleeding could be decreased by
improving or eliminating ascites, total bilirubin level, Child-
Pugh classification and RCS by means of ascites
paracenteses, diuretics, hepato-protectors and portal
pressure lowering drugs. Child Pugh B and Child
Pugh C needs to have endoscopic procedure and
evaluation of risk factors over time. This study should
be followed by another study with longer evaluation
period and more valid measurement.
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